Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Supplementary Documents of Financial Results for FY2024
ASKA Receives Highest Rating in DBJ Employees' Health Management Rated Loan Program by Development Bank of Japan and Financed by Same Loan
Changes in Organizational, Personnel, and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
Organizational and Personnel Change of ASKA Pharmaceutical Holdings
Change in Personnel and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
Personnel Changes in Board Members and Corporate Officers of ASKA Pharmaceutical Holdings’ Subsidiaries
Personnel Changes of Board Members and Corporate Officers
Notice: Changes in Representative Directors, ASKA Pharmaceutical Holdings
ASKA Announces Phase III Clinical Trial Result of TRM-270
ASKA Selected under the FY2024 “Next Nadeshiko Companies Supporting Dual-career and Co-parenting”
ASKA Pharmaceutical Holdings Announces Cancellation of Treasury Shares
ASKA Pharmaceutical Holdings Group Recognized as White 500 Enterprise for Seventh Consecutive Year
ASKA Initiates Phase I II Clinical Trial of Drospirenone Agent (LPRI-CF113) in Japan
ASKA Pharmaceutical Holdings to Collaborate with MedChoice Pharma Inc through Share Acquisition of FTS Ambrose Holdings Inc.
Personnel Changes of ASKA Pharmaceutical Holdings
Organizational and Personnel Changes of ASKA Pharmaceutical
Consolidated Financial Results for the Third Quarter of FY2024
Notice Concerning Consolidation of Ha Tay Pharmaceutical Joint Stock Company as Consolidated Subsidiary
Supplementary Documents for 3Q FY2024
ASKA Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 3%, Oct-Dec Ordinary Profit Decreases by 16%